13F Pro13F Pro

SEC Form 4 reporting owner

Ra Capital Management, L.P.

Ra Capital Management, L.P. has filed 186 Form 4 transactions reported between December 8, 2025 and November 16, 2026, as a reporting owner of SpyGlass Pharma, Inc., a reporting owner of PepGen Inc., a reporting owner of Bambusa Therapeutics, Inc., a reporting owner of LENZ Therapeutics, Inc., a reporting owner of Wave Life Sciences, Inc., a reporting owner of Vor Biopharma Inc., a reporting owner of Climb Bio, Inc., a reporting owner of Sionna Therapeutics, Inc., a reporting owner of Tyra Biosciences, Inc., a reporting owner of Artiva Biotherapeutics, Inc., a reporting owner of Septerna, Inc., a reporting owner of Inhibikase Therapeutics, Inc., a reporting owner of Parabilis Medicines, Inc., a reporting owner of Freenome, Inc., a reporting owner of ARS Pharmaceuticals, Inc., a reporting owner of Acrivon Therapeutics, Inc., a reporting owner of Werewolf Therapeutics, Inc., a reporting owner of Hemab Therapeutics Holdings, Inc., a reporting owner of Janux Therapeutics, Inc., a reporting owner of Nkarta, Inc., a reporting owner of Bicara Therapeutics Inc., a reporting owner of Acumen Pharmaceuticals, Inc., a reporting owner of Adicet Bio, Inc., a reporting owner of Prelude Therapeutics Inc, a reporting owner of Mineralys Therapeutics, Inc., a reporting owner of Evommune, Inc. and a reporting owner of Fulcrum Therapeutics, Inc..

Name as filed: RA CAPITAL MANAGEMENT, L.P.

Follow Ra Capital Management, L.P. and get an alert on every new Form 4

Ra Capital Management, L.P. holds at least 11.6M shares of TYRA, worth $229.2M, 16.82% of the company.

As of their Sep 15, 2026 Form 4 · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $19.73 · 69.1M shares outstanding on Nov 6, 2026

Counted from the latest direct line and the latest indirect line that traded. Shares held through other trusts or entities that did not trade are not included yet, so the true holding can be larger.

Ra Capital Management, L.P. holds 4.5M shares of VOR, worth $83.4M, 7.33% of the company.

As of their Oct 2, 2026 Form 4 (filed Oct 5, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $18.52 · 61.4M shares outstanding on Oct 26, 2026

Ra Capital Management, L.P. holds at least 5.8M shares of MLYS, worth $82.5M, 6.58% of the company.

As of their Mar 30, 2026 Form 4 · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $14.16 · 88.6M shares outstanding on Oct 29, 2026

Counted from the latest direct line and the latest indirect line that traded. Shares held through other trusts or entities that did not trade are not included yet, so the true holding can be larger.

Holdings in 17 more companies are listed under Roles and reported holdings below.

Open-market buys, 24 mo
$575.6M
63 lines
Open-market sales, 24 mo
$171.5M
45 lines
Companies
27
with Form 4 filings
Latest transaction
Nov 16, 2026
transaction date

Roles and reported holdings

  • SGPSpyGlass Pharma, Inc.
    Feb 5, 2026 – Nov 16, 2026

    Reporting owner

    See footnotes2,054,678 sh

    As of Nov 16, 2026 · Form 4

    24 months: $32K bought

    2 lines are priced far from SGP’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

  • PEPGPepGen Inc.
    Jun 18, 2026 – Nov 13, 2026

    Reporting owner

    See footnotes207,672 sh

    Also reports 34,000 Stock Option (Right to Buy), not counted as shares.

    As of Nov 13, 2026 · Form 4

    24 months: $43.1M bought

  • BBTXBambusa Therapeutics, Inc.
    Oct 30, 2026 – Nov 2, 2026

    Reporting owner

    See footnotes1,495,971 sh

    As of Oct 30, 2026 · Form 4

    24 months: $46.6M bought

  • LENZLENZ Therapeutics, Inc.
    Jun 15, 2026 – Oct 29, 2026

    Reporting owner

    See footnotes57,559 sh

    Also reports 22,100 Stock Option (right to buy), not counted as shares.

    As of Oct 29, 2026 · Form 4

    24 months: $9.1M sold

  • WVEWave Life Sciences, Inc.
    Mar 26, 2026 – Oct 5, 2026

    Reporting owner

    See footnotes26,975,505 sh

    Also reports 64,000 Stock Option (Right to Buy), not counted as shares.

    As of Oct 5, 2026 · Form 4

    24 months: $54.6M bought

  • VORVor Biopharma Inc.
    Dec 18, 2025 – Oct 2, 2026

    Reporting owner

    See footnotes4,503,382 sh

    Also reports 7.9M Pre-Funded Warrant (Right to Buy), not counted as shares.

    As of Oct 2, 2026 · Form 4

    Shares held, direct and indirect, VOR, after each Form 4
    4.5M4.5M4.5MJul 16, 2026: 4.5M shares (Form 4)Aug 24, 2026: 4.5M shares (Form 4)Oct 2, 2026: 4.5M shares (Form 4)Jul 16, 2026Oct 2, 2026
    FilingShares afterChange
    Oct 2, 20264.5M+1,500
    Aug 24, 20264.5Mno change
    Jul 16, 20264.5M—

    24 months: $49.4M sold

  • CLYMClimb Bio, Inc.
    Dec 11, 2025 – Sep 28, 2026

    Reporting owner

    See footnotes841,087 sh

    As of Sep 28, 2026 · Form 4

    24 months: $780K bought

  • SIONSionna Therapeutics, Inc.
    Jun 17, 2026 – Sep 17, 2026

    Reporting owner

    See footnotes159,033 sh

    Also reports 17,340 Non-Qualified Stock Option (right to buy), not counted as shares.

    As of Sep 17, 2026 · Form 4

    24 months: $21.8M sold

  • TYRATyra Biosciences, Inc.
    May 28, 2026 – Sep 15, 2026

    Reporting owner

    Indirect (latest line that moved)11,616,986 sh

    As of Sep 15, 2026 · Form 4

    24 months: $200.0M bought

  • ARTVArtiva Biotherapeutics, Inc.
    May 11, 2026 – Sep 10, 2026

    Reporting owner

    See footnotes68,320 sh as of Jul 29, 2026

    Also reports 16,250 Director Stock Option (Right to Buy), not counted as shares.

    As of Sep 10, 2026 · Form 4

    Shares held, direct and indirect, ARTV, after each Form 4
    09.1M18.2MJun 12, 2026: 68K shares (Form 4)Jun 25, 2026: 68K shares (Form 4)Jul 10, 2026: 68K shares (Form 4)Jul 13, 2026: 16.8M shares (Form 4/A)Jul 16, 2026: 68K shares (Form 4)Jul 21, 2026: 68K shares (Form 4)Jul 24, 2026: 68K shares (Form 4)Jul 29, 2026: 68K shares (Form 4)Sep 8, 2026: 68K shares (Form 4)Sep 10, 2026: 68K shares (Form 4)Jun 12, 2026Sep 10, 2026
    FilingShares afterChange
    Sep 10, 202668Kno change
    Sep 8, 202668Kno change
    Jul 29, 202668Kno change
    Jul 24, 202668Kno change
    Jul 21, 202668Kno change
    Jul 16, 202668K−16.7M
    Jul 13, 202616.8M+16.7M
    Jul 10, 202668Kno change
    Jun 25, 202668Kno change
    Jun 12, 202668K—

    24 months: $117.6M bought

  • SEPNSepterna, Inc.
    Jun 26, 2026 – Aug 12, 2026

    Reporting owner

    See footnotes725,443 sh

    Also reports 15,000 Stock Option (Right to Buy), not counted as shares.

    As of Aug 12, 2026 · Form 4

    24 months: $31.7M sold

  • IKTInhibikase Therapeutics, Inc.
    Jul 29, 2026

    Reporting owner

    See footnotes6,970,000 sh

    Also reports 18.0M Pre-Funded Warrant (Right to Buy), not counted as shares.

    As of Jul 29, 2026 · Form 4

  • PBLSParabilis Medicines, Inc.
    Jun 9, 2026 – Jul 22, 2026

    Reporting owner

    See footnotes2,648,278 sh

    As of Jul 20, 2026 · Form 4

    Shares held, direct and indirect, PBLS, after each Form 4
    085.8M171.6MJun 11, 2026: 158.9M shares (Form 4)Jul 20, 2026: 2.6M shares (Form 4)Jun 11, 2026Jul 20, 2026
    FilingShares afterChange
    Jul 20, 20262.6M−156.2M
    Jun 11, 2026158.9M—

    24 months: $6.9M bought

    2 lines are priced far from PBLS’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

  • FRNMFreenome, Inc.
    Jul 20, 2026

    Reporting owner

    See footnotes1,245,068 sh

    As of Jul 20, 2026 · Form 4

  • SPRYARS Pharmaceuticals, Inc.
    Jun 24, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • ACRVAcrivon Therapeutics, Inc.
    Apr 22, 2026 – Jun 17, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • HOWLWerewolf Therapeutics, Inc.
    May 8, 2026 – Jun 17, 2026

    Reporting owner

    See footnotes303,719 sh

    As of Jun 17, 2026 · Form 4

    Shares held, direct and indirect, HOWL, after each Form 4
    300K317K334KJun 12, 2026: 331K shares (Form 4)Jun 17, 2026: 304K shares (Form 4)Jun 12, 2026Jun 17, 2026
    FilingShares afterChange
    Jun 17, 2026304K−28K
    Jun 12, 2026331K—

    24 months: $964K sold

  • COAGHemab Therapeutics Holdings, Inc.
    May 4, 2026 – Jun 16, 2026

    Reporting owner

    See footnotes354,938 sh

    As of Jun 15, 2026 · Form 4

    24 months: $55.5M bought

  • JANXJanux Therapeutics, Inc.
    Jun 11, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • NKTXNkarta, Inc.
    Jun 10, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • BCAXBicara Therapeutics Inc.
    Feb 26, 2026 – Jun 9, 2026

    Reporting owner

    Indirect (latest line that moved)2,200,000 sh

    As of Feb 26, 2026 · Form 4

    24 months: $40.0M bought

  • ABOSAcumen Pharmaceuticals, Inc.
    Mar 16, 2026 – Jun 3, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • ACETAdicet Bio, Inc.
    Feb 18, 2026 – Apr 27, 2026

    Reporting owner

    Indirect (latest line that moved)1,182,624 sh

    As of Feb 20, 2026 · Form 4

    24 months: $1.6M bought

  • PRLDPrelude Therapeutics Inc
    Apr 27, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • MLYSMineralys Therapeutics, Inc.
    Feb 19, 2026 – Mar 30, 2026

    Reporting owner

    Indirect (latest line that moved)5,825,521 sh

    As of Mar 30, 2026 · Form 4

    24 months: $8.8M bought

  • EVMNEvommune, Inc.
    Feb 17, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • FULCFulcrum Therapeutics, Inc.
    Dec 8, 2025

    Reporting owner

    Indirect (latest line that moved)6,053,960 sh

    As of Dec 8, 2025 · Form 4

    24 months: $58.4M sold

How their buys did since

63 open-market purchases against today’s price: +0.2% on average, -16.4% weighted by dollars spent.

DatePaidReturn
Nov 16, 2026SGP$32.43-5.1%now $30.78
Nov 13, 2026PEPG$5.00-21.4%now $3.93
Nov 2, 2026BBTX$16.00-2.8%now $15.55
Nov 2, 2026BBTX$16.00-2.8%now $15.55
Oct 30, 2026BBTX$14.92+4.2%now $15.55
Oct 30, 2026BBTX$14.23+9.3%now $15.55
Sep 15, 2026TYRA$22.03-10.4%now $19.73
Jul 31, 2026ARTV$9.93-61.4%now $3.83
Jul 29, 2026ARTV$9.99-61.7%now $3.83
Jul 24, 2026ARTV$9.99-61.7%now $3.83
Jul 23, 2026ARTV$9.96-61.5%now $3.83
Jul 22, 2026ARTV$9.93-61.4%now $3.83
Jul 22, 2026PBLS$29.77-7.2%now $27.62
Jul 21, 2026ARTV$9.55-59.9%now $3.83
Jul 21, 2026PBLS$30.00-7.9%now $27.62
Jul 21, 2026PBLS$29.17-5.3%now $27.62
Jul 21, 2026PBLS$27.96-1.2%now $27.62
Jul 20, 2026PBLS$27.72-0.4%now $27.62
Jul 20, 2026PBLS$27.13+1.8%now $27.62
Jul 17, 2026ARTV$8.95-57.2%now $3.83
Jul 16, 2026ARTV$8.93-57.1%now $3.83
Jul 13, 2026ARTV$8.94-57.2%now $3.83
Jul 10, 2026ARTV$8.97-57.3%now $3.83
Jun 26, 2026ARTV$8.98-57.4%now $3.83
Jun 25, 2026ARTV$8.88-56.9%now $3.83
Jun 16, 2026ARTV$8.89-56.9%now $3.83
Jun 16, 2026COAG$24.98+59.6%now $39.86
Jun 15, 2026ARTV$8.99-57.4%now $3.83
Jun 15, 2026COAG$24.89+60.1%now $39.86
Jun 12, 2026ARTV$8.57-55.3%now $3.83
Jun 11, 2026ARTV$7.91-51.6%now $3.83
Jun 10, 2026ARTV$7.00-45.3%now $3.83
Jun 9, 2026ARTV$6.91-44.6%now $3.83
May 20, 2026COAG$24.94+59.8%now $39.86
May 19, 2026COAG$24.97+59.6%now $39.86
May 12, 2026COAG$24.90+60.1%now $39.86
May 11, 2026ARTV$11.52-66.8%now $3.83
May 11, 2026ARTV$11.52-66.8%now $3.83
May 11, 2026COAG$25.00+59.4%now $39.86
May 11, 2026COAG$24.47+62.9%now $39.86
May 8, 2026COAG$24.98+59.6%now $39.86
May 7, 2026COAG$24.95+59.8%now $39.86
May 7, 2026COAG$24.34+63.8%now $39.86
May 6, 2026COAG$24.83+60.5%now $39.86
May 6, 2026COAG$23.77+67.7%now $39.86
May 5, 2026COAG$25.00+59.4%now $39.86
May 5, 2026COAG$24.59+62.1%now $39.86
May 4, 2026COAG$18.00+121.4%now $39.86
May 4, 2026COAG$18.00+121.4%now $39.86
Mar 30, 2026WVE$6.50-58.1%now $2.72
Mar 30, 2026MLYS$24.16-41.4%now $14.16
Mar 27, 2026WVE$6.43-57.7%now $2.72
Mar 27, 2026MLYS$23.67-40.2%now $14.16
Mar 26, 2026WVE$6.38-57.4%now $2.72
Mar 26, 2026WVE$6.06-55.1%now $2.72
Feb 26, 2026BCAX$16.00-43.0%now $9.12
Feb 26, 2026BCAX$16.00-43.0%now $9.12
Feb 20, 2026ACET$7.27-66.2%now $2.46
Feb 19, 2026ACET$7.21-65.9%now $2.46
Feb 18, 2026ACET$7.04-65.1%now $2.46
Jan 5, 2026CLYM$3.50+165.1%now $9.28
Dec 12, 2025CLYM$2.86+224.5%now $9.28
Dec 11, 2025CLYM$2.18+325.7%now $9.28

Each purchase at the price on its Form 4, against the latest trade or close, adjusted for stock splits. Past returns say nothing about future ones.

Transaction history

All 186 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Nov 16, 2026SGPOpen-market purchaseCode P · indirect1,000$32K@ $32.43Form 4
Nov 13, 2026PEPGOpen-market purchaseCode P · indirect8,625,000$43.1M@ $5.00Form 4
Nov 2, 2026BBTXConversion of derivativeCode C · indirect52,932—Form 4
Nov 2, 2026BBTXConversion of derivativeCode C · indirect299,948—Form 4
Nov 2, 2026BBTXConversion of derivativeCode C · indirect1,278,148—Form 4
Nov 2, 2026BBTXConversion of derivativeCode C · indirect2,844,910—Form 4
Nov 2, 2026BBTXOpen-market purchaseCode P · indirect164,891$2.6M@ $16.00Form 4
Nov 2, 2026BBTXOpen-market purchaseCode P · indirect2,335,109$37.4M@ $16.00Form 4
Nov 2, 2026BBTXConversion of derivativeCode C · indirect1,331,080—Form 4
Nov 2, 2026BBTXConversion of derivativeCode C · indirect3,144,858—Form 4
Oct 30, 2026BBTXOpen-market purchaseCode P · indirect263,911$3.9M@ $14.92Form 4
Oct 30, 2026BBTXOpen-market purchaseCode P · indirect189,909$2.7M@ $14.23Form 4
Oct 29, 2026LENZOpen-market saleCode S · indirect107,170$360K@ $3.36Form 4
Oct 29, 2026LENZOpen-market saleCode S · indirect451,998$1.5M@ $3.36Form 4
Oct 29, 2026LENZOpen-market saleCode S · indirect2,159,516$7.3M@ $3.36Form 4
Oct 5, 2026WVEGrant or awardCode A · indirect64,000—Form 4
Oct 5, 2026WVEGrant or awardCode A · indirect10,700—Form 4
Oct 2, 2026VOROption exerciseCode M · indirect500$6K@ $12.80Form 4
Sep 28, 2026CLYMOption exerciseCode M · indirect40,000$52K@ $1.29Form 4
Sep 28, 2026CLYMOption exerciseCode M · indirect10,000$35K@ $3.46Form 4
Sep 17, 2026SIONOpen-market saleCode S · indirect33,800$252K@ $7.46Form 4
Sep 17, 2026SIONOpen-market saleCode S · indirect3,415,011$21.6M@ $6.32Form 4
Sep 15, 2026TYRAOpen-market purchaseCode P · indirect9,078,529$200.0M@ $22.03Form 4
Sep 10, 2026ARTVGrant or awardCode A · indirect16,250—Form 4
Sep 8, 2026ARTVGrant or awardCode A · indirect13,750—Form 4
Aug 24, 2026VOROption exerciseCode M · indirect1,500$6K@ $3.74Form 4
Aug 12, 2026SEPNOpen-market saleCode S · indirect746,500$31.7M@ $42.50Form 4
Jul 31, 2026ARTVOpen-market purchaseCode P · indirect24,944$248K@ $9.93Form 4
Jul 29, 2026ARTVOpen-market purchaseCode P · indirect20,824$208K@ $9.99Form 4
Jul 29, 2026IKTOther acquisition or dispositionCode J · indirect18,030,000—Form 4
Jul 24, 2026ARTVOpen-market purchaseCode P · indirect41,319$413K@ $9.99Form 4
Jul 23, 2026ARTVOpen-market purchaseCode P · indirect59,880$596K@ $9.96Form 4
Jul 22, 2026ARTVOpen-market purchaseCode P · indirect84,124$835K@ $9.93Form 4
Jul 22, 2026PBLSOpen-market purchaseCode P · indirect47,250$1.4M@ $29.77Form 4
Jul 21, 2026ARTVOpen-market purchaseCode P · indirect120,582$1.2M@ $9.55Form 4
Jul 21, 2026PBLSOpen-market purchaseCode P · indirect37,723$1.1M@ $30.00Form 4
Jul 21, 2026PBLSOpen-market purchaseCode P · indirect6,504$190K@ $29.17Form 4
Jul 21, 2026PBLSOpen-market purchaseCode P · indirect21,696$607K@ $27.96Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect336,965$3.4M@ $10.00Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect4,918,411$49.2M@ $10.00Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect367,427—Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect908,103—Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect553,703—Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect970,950—Form 4
Jul 20, 2026FRNMGrant or awardCode A · indirect6,561,711—Form 4
Jul 20, 2026PBLSOpen-market purchaseCode P · indirect32,987$914K@ $27.72Form 4
Jul 20, 2026PBLSOpen-market purchaseCode P · indirect98,433$2.7M@ $27.13Form 4
Jul 17, 2026ARTVOpen-market purchaseCode P · indirect7,882$71K@ $8.95Form 4
Jul 16, 2026VOROpen-market saleCode S · indirect213$4K@ $19.75Form 4
Jul 16, 2026VOROption exerciseCode X · indirect2,100,000$4K@ $0.0020Form 4
Jul 16, 2026ARTVOpen-market purchaseCode P · indirect152,472$1.4M@ $8.93Form 4
Jul 13, 2026ARTVOpen-market purchaseCode P · indirect6,552$59K@ $8.94Form 4
Jul 10, 2026ARTVOpen-market purchaseCode P · indirect15,102$135K@ $8.97Form 4
Jun 29, 2026CLYMGrant or awardCode A · indirect70,284—Form 4
Jun 26, 2026ARTVOpen-market purchaseCode P · indirect1,876$17K@ $8.98Form 4
Jun 26, 2026SEPNGrant or awardCode A · indirect15,000—Form 4
Jun 25, 2026ARTVOpen-market purchaseCode P · indirect31,000$275K@ $8.88Form 4
Jun 24, 2026SPRYGrant or awardCode A · indirect30,000—Form 4
Jun 18, 2026PEPGGrant or awardCode A · indirect34,000—Form 4
Jun 17, 2026ACRVGrant or awardCode A · indirect20,275—Form 4
Jun 17, 2026HOWLOpen-market saleCode S · indirect27,695$10K@ $0.3500Form 4
Jun 17, 2026HOWLOpen-market saleCode S · indirect389,216$136K@ $0.3500Form 4
Jun 17, 2026SIONGrant or awardCode A · indirect17,340—Form 4
Jun 16, 2026ARTVOpen-market purchaseCode P · indirect124,893$1.1M@ $8.89Form 4
Jun 16, 2026COAGOpen-market purchaseCode P · indirect61,523$1.5M@ $24.98Form 4
Jun 16, 2026HOWLOpen-market saleCode S · indirect9,939$4K@ $0.3700Form 4
Jun 16, 2026HOWLOpen-market saleCode S · indirect139,686$52K@ $0.3700Form 4
Jun 15, 2026ARTVOpen-market purchaseCode P · indirect15,414$139K@ $8.99Form 4
Jun 15, 2026COAGOpen-market purchaseCode P · indirect6,146$153K@ $24.89Form 4
Jun 15, 2026HOWLOpen-market saleCode S · indirect8,554$3K@ $0.3900Form 4
Jun 15, 2026HOWLOpen-market saleCode S · indirect120,216$47K@ $0.3900Form 4
Jun 15, 2026LENZGrant or awardCode A · indirect22,100—Form 4
Jun 12, 2026ARTVOpen-market purchaseCode P · indirect391,019$3.4M@ $8.57Form 4
Jun 12, 2026HOWLOpen-market saleCode S · indirect11,322$5K@ $0.4000Form 4
Jun 12, 2026HOWLOpen-market saleCode S · indirect159,119$64K@ $0.4000Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect1,666,829—Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect9,445,363—Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect160,562—Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect642,250—Form 4
Jun 11, 2026PBLSOpen-market purchaseCode P · indirectPrice far from market; may be another security1,460,397$29.2M@ $20.00Form 4
Jun 11, 2026PBLSOpen-market purchaseCode P · indirectPrice far from market; may be another security19,728,353$394.6M@ $20.00Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect1,187,881—Form 4
Jun 11, 2026PBLSConversion of derivativeCode C · indirect6,556,740—Form 4
Jun 11, 2026ARTVOpen-market purchaseCode P · indirect548,580$4.3M@ $7.91Form 4
Jun 11, 2026JANXGrant or awardCode A · indirect15,500—Form 4
Jun 11, 2026JANXGrant or awardCode A · indirect5,500—Form 4
Jun 11, 2026VORGrant or awardCode A · indirect57,162—Form 4
Jun 11, 2026HOWLOpen-market saleCode S · indirect17,437$7K@ $0.3800Form 4
Jun 11, 2026HOWLOpen-market saleCode S · indirect245,066$93K@ $0.3800Form 4
Jun 10, 2026ARTVOpen-market purchaseCode P · indirect103$721@ $7.00Form 4
Jun 10, 2026HOWLOpen-market saleCode S · indirect3,051$1K@ $0.3700Form 4
Jun 10, 2026HOWLOpen-market saleCode S · indirect42,872$16K@ $0.3700Form 4
Jun 10, 2026NKTXGrant or awardCode A · indirect37,000—Form 4
Jun 9, 2026PBLSGrant or awardCode A · indirect20,215—Form 4
Jun 9, 2026ARTVOpen-market purchaseCode P · indirect479,039$3.3M@ $6.91Form 4
Jun 9, 2026BCAXGrant or awardCode A · indirect19,475—Form 4
Jun 9, 2026HOWLOpen-market saleCode S · indirect24,565$9K@ $0.3700Form 4
Jun 9, 2026HOWLOpen-market saleCode S · indirect345,235$128K@ $0.3700Form 4
Jun 5, 2026CLYMGrant or awardCode A · indirect40,000—Form 4
Jun 3, 2026ABOSGrant or awardCode A · indirect53,250—Form 4
Jun 3, 2026ABOSGrant or awardCode A · indirect35,500—Form 4
May 28, 2026TYRAGrant or awardCode A · indirect13,160—Form 4
May 20, 2026COAGOpen-market purchaseCode P · indirect996$25K@ $24.94Form 4
May 19, 2026COAGOpen-market purchaseCode P · indirect3,802$95K@ $24.97Form 4
May 18, 2026ACRVGrant or awardCode A · indirect9,366—Form 4
May 12, 2026COAGOpen-market purchaseCode P · indirect6,387$159K@ $24.90Form 4
May 12, 2026HOWLOpen-market saleCode S · indirect6,719$4K@ $0.6400Form 4
May 12, 2026HOWLOpen-market saleCode S · indirect94,432$60K@ $0.6400Form 4
May 11, 2026ARTVOpen-market purchaseCode P · indirect2,170,138$25.0M@ $11.52Form 4
May 11, 2026ARTVOpen-market purchaseCode P · indirect6,510,416$75.0M@ $11.52Form 4
May 11, 2026COAGOpen-market purchaseCode P · indirect25,720$643K@ $25.00Form 4
May 11, 2026COAGOpen-market purchaseCode P · indirect14,149$346K@ $24.47Form 4
May 11, 2026HOWLOpen-market saleCode S · indirect5,812$4K@ $0.6700Form 4
May 11, 2026HOWLOpen-market saleCode S · indirect81,678$55K@ $0.6700Form 4
May 8, 2026COAGOpen-market purchaseCode P · indirect1,483$37K@ $24.98Form 4
May 8, 2026HOWLOpen-market saleCode S · indirect25,012$18K@ $0.7100Form 4
May 8, 2026HOWLOpen-market saleCode S · indirect351,514$250K@ $0.7100Form 4
May 7, 2026COAGOpen-market purchaseCode P · indirect1,985$50K@ $24.95Form 4
May 7, 2026COAGOpen-market purchaseCode P · indirect7,921$193K@ $24.34Form 4
May 6, 2026COAGOpen-market purchaseCode P · indirect53,407$1.3M@ $24.83Form 4
May 6, 2026COAGOpen-market purchaseCode P · indirect14,611$347K@ $23.77Form 4
May 5, 2026COAGOpen-market purchaseCode P · indirect10,268$257K@ $25.00Form 4
May 5, 2026COAGOpen-market purchaseCode P · indirect87,143$2.1M@ $24.59Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect10,054—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect56,972—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect18,146—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect42,341—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect27,720—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect64,680—Form 4
May 4, 2026COAGOpen-market purchaseCode P · indirect133,750$2.4M@ $18.00Form 4
May 4, 2026COAGOpen-market purchaseCode P · indirect2,541,250$45.7M@ $18.00Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect221,188—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect1,009,052—Form 4
May 4, 2026COAGConversion of derivativeCode C · indirect3,607,846—Form 4
Apr 29, 2026CLYMGrant or awardCode A · indirect2,106,000$20.0M@ $9.50Form 4
Apr 27, 2026ACETOther acquisition or dispositionCode J · indirect250,000—Form 4
Apr 27, 2026PRLDOther acquisition or dispositionCode J · indirect1,407,000—Form 4
Apr 22, 2026VOROpen-market saleCode S · indirect165,150$2.6M@ $15.77Form 4
Apr 22, 2026ACRVGrant or awardCode A · indirect3,888,888$7.0M@ $1.80Form 4
Apr 20, 2026VOROpen-market saleCode S · indirect171,963$2.7M@ $15.77Form 4
Apr 17, 2026VOROpen-market saleCode S · indirect458,411$7.5M@ $16.28Form 4
Apr 15, 2026VOROpen-market saleCode S · indirect53,644$859K@ $16.01Form 4
Apr 14, 2026VOROpen-market saleCode S · indirect153,735$2.5M@ $15.97Form 4
Apr 13, 2026VOROpen-market saleCode S · indirect530,610$8.6M@ $16.15Form 4
Apr 10, 2026VOROpen-market saleCode S · indirect828$13K@ $15.75Form 4
Apr 9, 2026VOROpen-market saleCode S · indirect135,201$2.2M@ $16.59Form 4
Apr 8, 2026VOROpen-market saleCode S · indirect130,862$2.2M@ $16.91Form 4
Apr 8, 2026VOROpen-market saleCode S · indirect353,242$5.8M@ $16.32Form 4
Apr 6, 2026VOROpen-market saleCode S · indirect6,775$125K@ $18.50Form 4
Apr 6, 2026VOROpen-market saleCode S · indirect44,728$774K@ $17.31Form 4
Apr 6, 2026VOROpen-market saleCode S · indirect537,754$8.9M@ $16.51Form 4
Apr 2, 2026VOROpen-market saleCode S · indirect1,525$29K@ $19.06Form 4
Apr 2, 2026VOROpen-market saleCode S · indirect258,475$4.7M@ $18.23Form 4
Mar 30, 2026WVEOpen-market purchaseCode P · indirect971,091$6.3M@ $6.50Form 4
Mar 30, 2026MLYSOpen-market purchaseCode P · indirect58,300$1.4M@ $24.16Form 4
Mar 27, 2026WVEOpen-market purchaseCode P · indirect2,495,623$16.0M@ $6.43Form 4
Mar 27, 2026MLYSOpen-market purchaseCode P · indirect310,700$7.4M@ $23.67Form 4
Mar 26, 2026WVEOpen-market purchaseCode P · indirect351,224$2.2M@ $6.38Form 4
Mar 26, 2026WVEOpen-market purchaseCode P · indirect4,954,558$30.0M@ $6.06Form 4
Mar 16, 2026ABOSGrant or awardCode A · indirect6,060,606$20.0M@ $3.30Form 4
Feb 26, 2026BCAXOpen-market purchaseCode P · indirect2,200,000$35.2M@ $16.00Form 4
Feb 26, 2026BCAXOpen-market purchaseCode P · indirect300,000$4.8M@ $16.00Form 4
Feb 20, 2026ACETOpen-market purchaseCode P · indirect74,751$543K@ $7.27Form 4
Feb 19, 2026ACETOpen-market purchaseCode P · indirect74,268$535K@ $7.21Form 4
Feb 19, 2026MLYSGrant or awardCode A · indirect8,300—Form 4
Feb 19, 2026MLYSGrant or awardCode A · indirect6,200—Form 4
Feb 18, 2026ACETOpen-market purchaseCode P · indirect74,577$525K@ $7.04Form 4
Feb 17, 2026EVMNGrant or awardCode A · indirect35,868$1000K@ $27.88Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect272,056—Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect222,591—Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect767,294—Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect1,150,941—Form 4
Feb 9, 2026SGPOpen-market purchaseCode P · indirectPrice far from market; may be another security248,034$4.0M@ $16.00Form 4
Feb 9, 2026SGPOpen-market purchaseCode P · indirectPrice far from market; may be another security3,441,966$55.1M@ $16.00Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect1,806,644—Form 4
Feb 9, 2026SGPConversion of derivativeCode C · indirect2,524,473—Form 4
Feb 5, 2026SGPGrant or awardCode A · indirect27,400—Form 4
Jan 5, 2026CLYMOpen-market purchaseCode P · indirect7,111$25K@ $3.50Form 4
Dec 18, 2025VORGrant or awardCode A · indirect3,000—Form 4
Dec 18, 2025VORGrant or awardCode A · indirect4,625,346$50.0M@ $10.81Form 4
Dec 12, 2025CLYMOpen-market purchaseCode P · indirect101,462$290K@ $2.86Form 4
Dec 11, 2025CLYMOpen-market purchaseCode P · indirect213,099$465K@ $2.18Form 4
Dec 11, 2025CLYMDisposition to issuerCode D · indirect20,440,000—Form 4
Dec 8, 2025FULCOpen-market saleCode S · indirect91,722$1.4M@ $14.98Form 4
Dec 8, 2025FULCOpen-market saleCode S · indirect2,706,397$38.6M@ $14.28Form 4
Dec 8, 2025FULCOpen-market saleCode S · indirect1,377,020$18.4M@ $13.33Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares each ownership line is left at by the person’s latest Form 4, 4/A or 5: held directly, and through each trust or entity named on the filing. A second class of common stock that converts into the listed one counts as shares; options and restricted stock units are listed but not counted. Value uses the latest trade or close, and the share of the company uses the latest shares-outstanding count the company reported. Where a filing has not yet been read line by line, the figure comes from the latest direct and indirect lines that traded and is shown as “at least”.

4 open-market lines are priced outside 0.67×–1.5× of the stock’s closing price that day. A gap that large usually means the filing reports a different security than the company it is filed under, so those lines are shown but left out of totals and holdings.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.